Skip to main content

Table 1 Subset of demographics and chemotherapy regimens for study participants receiving treatment for breast cancer

From: Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study

Treatment/demographic factor Black participants
N = 22 (30.6%)
White participants
N = 50 (69.4%)
Therapy regimen TAC1
n = 10 (45%)2
TC1
n = 6 (27%)
TCH1
n = 6 (27%)
Total
n = 22 (100%)
TAC1
n = 29 (58%)
TC1
n = 15 (30%)
TCH1
n = 6(12%)
Total
n = 50(100%)
Age 44.0 [3.4]3 47.0 [2.5] 50.5 [2.9] 46.6 [2.1] 52.2 [1.7] 57.1 [2.6] 51.0 [5.2] 53.5 [1.4]
Income
 Less than $30,000 5 (23%) 4 (18%) 3 (14%) 12 (55%) 6 (12%) 1 (2%) 0 (0%) 7 (14%)
 $30,000–$59,999 3 (14%) 2 (9%) 3 (14%) 8 (37%) 5 (10%) 1 (2%) 0 (0%) 6 (12%)
 $60,000–$89,999 1 (4%) 0 (0%) 0 (0%) 1 (4%) 8 (16%) 7 (14%) 3 (6%) 18 (36%)
 $90,000+ 1 (4%) 0 (0%) 0 (0%) 1 (4%) 10 (20%) 6 (12%) 3 (6%) 19 (36%)
  1. 1TAC = sequential administration of docetaxel (Taxotere), doxorubicin (Adriamycin), and cyclophosphamide (Cytoxan); TC = docetaxel (Taxotere) and cyclophosphamide (Cytoxan); TCH = docetaxel (Taxotere), Carboplatin (Paraplatin), and trastuzumab (Herceptin)
  2. 2Number in parentheses is the percentage of participants in this category (%)
  3. 3Mean and [standard error] for age is shown, respectively